Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters

Publication year range
1.
World J Urol ; 37(2): 359-365, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29967948

ABSTRACT

PURPOSE: To compare between deep neuromuscular blockade (NMB) and moderate NMB with respect to endoscopic surgical conditions and recovery profiles in patients with general anesthesia for transurethral resection of bladder (TURB). METHODS: 108 patients undergoing elective TURB were randomized into two groups: the moderate NMB (n = 54) or deep NMB (n = 54) group. After the operation, NMB was reversed with 2 mg/kg sugammadex at a train-of-four (TOF) count of 1 or 2 (moderate NMB group) or with 4 mg/kg sugammadex at post-tetanic count (PTC) of 2 (deep NMB group). Surgeons, who were blinded to the study design, rated the endoscopic surgical condition on a 5-point scale (1 = extremely poor, 2 = poor, 3 = acceptable, 4 = good, 5 = optimal) immediately following the operation. Recovery profiles, including postoperative residual curarization (PORC), respiratory complication, and recovery time, were recorded. RESULTS: No difference was observed between the two groups regarding patients and anesthesia characteristics. There were statistically significant differences in endoscopic surgical conditions between the two groups (P < 0.001). Thirty-eight patients in the deep NMB group (74%) showed optimal surgical conditions, whereas 16 patients in the moderate NMB group (30%) showed optimal endoscopic surgical conditions. No PORC and respiratory complications occurred in both groups, and no difference was found between the two groups in terms of recovery profiles, including recovery time and other adverse events. CONCLUSIONS: Deep NMB and reversal with sugammadex improved the endoscopic surgical condition without complications compared with moderate NMB and reversal with sugammadex in patients undergoing TURB.


Subject(s)
Cystectomy/methods , Neuromuscular Blockade/methods , Urinary Bladder Neoplasms/surgery , Aged , Aged, 80 and over , Anesthesia, General , Cystoscopy , Double-Blind Method , Elective Surgical Procedures , Humans , Male , Middle Aged , Prospective Studies , Recovery of Function
2.
Br J Anaesth ; 119(6): 1161-1168, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-29029049

ABSTRACT

Background: Intraoperative use of a high-dose remifentanil may induce postoperative hyperalgesia. Low-dose naloxone can selectively reverse some adverse effects of opioids without compromising analgesia. We thus hypothesized that the intraoperative use of a high-dose remifentanil combined with a low-dose naloxone infusion reduces postoperative hyperalgesia compared with the use of remifentanil alone. Methods: Patients undergoing elective thyroid surgery were randomly assigned into one of three groups, depending on the intraoperative effect-site concentration of remifentanil, with or without a continuous infusion of naloxone: 4 ng ml-1 remifentanil with 0.05 µg kg-1 h-1 naloxone in the high-remifentanil with naloxone group, and 4 or 1 ng ml-1 remifentanil with a placebo in the high- or low-remifentanil groups, respectively. We measured the pain thresholds (primary outcome) to mechanical stimuli using von Frey filaments and incidence of hyperalgesia on the peri-incisional area 24 h after surgery. We also measured pain intensity, analgesic consumptions and adverse events up to 48 h after surgery. Results: The pain threshold presented as von Frey numbers [median (interquartile range)] was significantly lower in the high-remifentanil group (n=31) than in the high-remifentanil with naloxone (n=30) and the low-remifentanil (n=30) groups [3.63 (3.22-3.84) vs 3.84 (3.76-4.00) vs 3.80 (3.69-4.08), P=0.011]. The incidence of hyperalgesia was also higher in the high-remifentanil group than in the other groups [21/31 vs 10/30 vs 9/30, P=0.005]. Postoperative pain intensity, analgesic consumptions and adverse events were similar between groups. Conclusions: The intraoperative use of low-dose naloxone combined with high-dose remifentanil reduced postoperative hyperalgesia but not pain. Clinical trial registration: NCT02856087.


Subject(s)
Analgesics, Opioid/adverse effects , Hyperalgesia/chemically induced , Intraoperative Care/methods , Naloxone/therapeutic use , Pain, Postoperative/chemically induced , Remifentanil/adverse effects , Adult , Aged , Double-Blind Method , Female , Humans , Hyperalgesia/prevention & control , Male , Middle Aged , Narcotic Antagonists/therapeutic use , Pain Measurement , Pain, Postoperative/prevention & control , Prospective Studies , Young Adult
3.
Anaesthesia ; 72(10): 1196-1205, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28891056

ABSTRACT

We studied the predictive performance of the Minto pharmacokinetic model during cardiopulmonary bypass in patients undergoing cardiac surgery. Patients received remifentanil target-controlled infusion using the Minto model during total intravenous anaesthesia with propofol. From 56 patients, 275 arterial blood samples were drawn before, during and after bypass to determine the plasma concentration of remifentanil, and the predicted concentrations were recorded at each time. For pooled data, the median prediction error and median absolute prediction error were 21.3% and 21.8%, respectively, and 22.1% and 22.3% during bypass. Both were 148.4% during hypothermic circulatory arrest and measured concentrations were more than three times greater than predicted (26.9 (17.0) vs. 7.1 (1.6) ng.ml-1 ). The Minto model showed considerable bias but overall acceptable precision during bypass. The target concentration of remifentanil should be reduced when using the Minto model during hypothermic circulatory arrest.


Subject(s)
Analgesics, Opioid/administration & dosage , Cardiopulmonary Bypass , Models, Biological , Remifentanil/administration & dosage , Adult , Aged , Analgesics, Opioid/blood , Anesthetics, Intravenous/administration & dosage , Double-Blind Method , Drug Administration Schedule , Drug Delivery Systems/methods , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Monitoring, Intraoperative/methods , Propofol/administration & dosage , Remifentanil/blood
4.
Acta Anaesthesiol Scand ; 60(9): 1281-8, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27377041

ABSTRACT

BACKGROUND: Few studies investigated the optimal timing for tracheostomy and its influence on the clinical outcomes in critically ill pediatric patients. This study evaluated the differences in clinical outcomes between early and late tracheostomy in pediatric intensive care unit (ICU) patients. METHODS: We assessed 111 pediatric patients. Patients who underwent a tracheostomy within 14 days of mechanical ventilation (MV) were assigned to the early tracheostomy group, whereas those who underwent tracheostomy after 14 days of MV were included in the late tracheostomy group. Clinical outcomes, including mortality, duration of MV, length of ICU and hospital stays, and incidence of ventilator-associated pneumonia (VAP) were compared between the groups. RESULTS: Of the 111 pediatric patients, 61 and 50 were included in the early and late tracheostomy groups, respectively. Total MV duration and the length of ICU and hospital stay were significantly longer in the late tracheostomy group than in the early tracheostomy group (all P < 0.01). The VAP rate per 1000 ventilator days before tracheostomy was 2.6 and 3.8 in the early and late tracheostomy groups, respectively. There were no significant differences in mortality rate between the groups. No severe complications were associated with tracheostomy itself. CONCLUSIONS: Tracheostomy performed within 14 days after the initiation of MV was associated with reduced duration of MV and length of ICU and hospital stay. Although there was no effect on mortality rate, children may benefit from early tracheostomy without severe complications.


Subject(s)
Critical Illness , Tracheostomy , Child , Child, Preschool , Female , Humans , Infant , Intensive Care Units, Pediatric , Length of Stay , Male , Pneumonia, Ventilator-Associated/epidemiology , Time Factors , Tracheostomy/mortality
5.
Sci Rep ; 13(1): 6966, 2023 Apr 28.
Article in English | MEDLINE | ID: mdl-37117263

ABSTRACT

To ease water scarcity, dynamic programming, stochastic dynamic programming, and heuristic algorithms have been applied to solve problem matters related to water resources. Development, operation, and management are vital in a reservoir operating policy, especially when the reservoir serves a complex objective. In this study, an attempt via metaheuristic algorithms, namely the Harris Hawks Optimisation (HHO) Algorithm and the Opposite Based Learning of HHO (OBL-HHO) are made to minimise the water deficit as well as mitigate floods at downstream of the Klang Gate Dam (KGD). Due to trade-offs between water supply and flood management, the HHO and OBL-HHO models have configurable thresholds to optimise the KGD reservoir operation. To determine the efficacy of the HHO and OBL-HHO in reservoir optimisation, reliability, vulnerability, and resilience are risk measures evaluated. If inflow categories are omitted, the OBL-HHO meets 71.49% of demand compared to 54.83% for the standalone HHO. The HHO proved superior to OBL-HHO in satisfying demand during medium inflows, achieving 38.60% compared to 20.61%, even though the HHO may have experienced water loss at the end of the storage level. The HHO is still a promising method, as proven by its reliability and resilience indices compared to other published heuristic algorithms: at 62.50% and 1.56, respectively. The Artificial Bee Colony (ABC) outcomes satisfied demand at 61.36%, 59.47% with the Particle Swarm Optimisation (PSO), 55.68% with the real-coded Genetic Algorithm (GA), and 23.5 percent with the binary GA. For resilience, the ABC scored 0.16, PSO scored 0.15, and real coded GA scored 0.14 whilst the binary-GA has the worst failure recovery algorithm with 0.09.

6.
J Clin Invest ; 80(4): 983-91, 1987 Oct.
Article in English | MEDLINE | ID: mdl-3477571

ABSTRACT

The C6-sulfidopeptide leukotrienes C4 (LTC4) and D4 (LTD4) evoked increases in the cytosolic concentration of intracellular calcium ([Ca+2]i) in dimethylsulfoxide-differentiated HL-60 cells, as assessed by the fluorescence of quin-2. The increases in [Ca+2]i reached a peak within 15-90 s, attained 50% of the maximum level at 1.2 nM LTD4 and 60 nM LTC4, were greater in maximal magnitude for LTD4 than LTC4, and subsided in 5-7 min. Flow cytometric evaluation of the LTD4-induced increases in [Ca+2]i, reflected in increases in the fluorescence of intracellular indo-1, revealed that a mean of 77% of differentiated HL-60 cells responded, as contrasted with lesser increases in only 50% of undifferentiated HL-60 cells. The capacity of pretreatment of HL-60 cells with LTD4 to prevent subsequent responses of [Ca+2]i to LTC4 and LTD4, and the finding that the serine-borate inhibitor of conversion of LTC4 to LTD4 suppressed concurrently both LTC4-induced rises in [Ca+2]i and increases in adherence to Sephadex G-25 indicated that the responses of HL-60 cells to LTC4 required conversion to LTD4. That pertussis toxin and a chemical antagonist of LTD4 reduced the [Ca+2]i response suggested a dependence on LTD4 receptors. The LTD4-induced increases in [Ca+2]i were dependent on extracellular calcium and diminished by lanthanum, but not affected by nifedipine nor associated with changes in membrane potential, as measured with the fluorescent probe 3,3'-dipentyloxacarbocyanine. Thus, the increase in [Ca+2]i in HL-60 cells, which is coupled to an increase in adherence, appears to involve LTD4 receptor-specific and voltage-independent calcium channels in the plasma membrane.


Subject(s)
Calcium/metabolism , Dimethyl Sulfoxide/pharmacology , Leukemia, Myeloid, Acute/metabolism , SRS-A/pharmacology , Aminoquinolines , Cell Differentiation/drug effects , Cell Line , Cytosol/drug effects , Cytosol/metabolism , Fluorescence , Humans , Indoles
7.
Medicine (Baltimore) ; 63(5): 274-90, 1984 Sep.
Article in English | MEDLINE | ID: mdl-6381957

ABSTRACT

This study is based on an analysis of the morphologic, clinical, and laboratory findings in 26 patients whose pretherapy lymph node biopsies showed some, but not all, of the diagnostic features of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Partial or complete effacement of nodal architecture by a diffuse lymphoplasmacytic and immunoblastic proliferation was a constant histologic finding. In contrast to the findings in AILD, lymphocytic depletion and pronounced arborizing vascular proliferation were often lacking. Clinically, many of the patients had fever, sweats, weight loss, skin rashes, generalized lymphadenopathy, hepatosplenomegaly, and, in some cases, pulmonary infiltrates. Of the 26 patients, 23 had clinical and/or laboratory evidence of autoimmune disease or immune complex disease. In 12 patients (Group I--idiopathic), various autoantibodies or immune complexes were demonstrable, but these patients did not manifest a well-defined immunologic disease or syndrome. In 11 patients (Group II--secondary), the lymphadenopathy occurred secondary to a well-defined, clinically recognized immunologic disease. Three patients (Group III) had neither a well-defined autoimmune disease nor demonstrable autoantibodies, but two of them had a history of exposure to antibiotics. We suggest that patients whose lymph nodes have the morphologic features described here frequently have an autoimmune disorder, and that the pathogenesis of this clinicopathologic picture is probably related to a deficiency in suppressor T-cell function which results in an unopposed proliferation of B cells with autoantibody formation and polyclonal gammopathy. Our observations should stimulate clinicians to consider the possibility of an autoimmune pathogenesis for a lymphadenopathy in which a florid lymphoplasmacytic and immunoblastic proliferation similar to that observed in AILD is demonstrated, even though the sections may not meet all the histologic criteria reported for the diagnosis of AILD. Clinical and laboratory investigations necessary to confirm the presence of autoimmunity are indicated in these cases. Moreover, since there is evidence of genetic factors predisposing to autoimmune disease (17, 43), it would be important to investigate close relatives of patients whose lymph nodes showed the histologic changes described in this paper in prospective studies which include suppressor T-cell function, autoantibodies, HLA type of blood lymphocytes and chromosomal analysis. The median survival of the 23 patients with stigmata of autoimmune disease or immune complex disease was 36 months.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Autoimmune Diseases/pathology , Immunoblastic Lymphadenopathy/pathology , Lymph Nodes/pathology , Lymphocytes/pathology , Plasma Cells/pathology , Adolescent , Adult , Aged , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Autopsy , Biopsy , Bone Marrow/pathology , Cell Division , Child , Female , Humans , Immunoblastic Lymphadenopathy/drug therapy , Immunoblastic Lymphadenopathy/immunology , Immunoenzyme Techniques , Liver/pathology , Lung/pathology , Lymph Nodes/blood supply , Male , Middle Aged , Skin/pathology , Spleen/pathology
8.
Am J Med ; 81(6): 1059-61, 1986 Dec.
Article in English | MEDLINE | ID: mdl-3799634

ABSTRACT

A patient with renal failure due to Goodpasture's syndrome was treated with vancomycin. After he had received 3 g of the drug, his white blood cell count fell to a level of 200/microliter. Bone marrow biopsy disclosed severe myeloid hypoplasia. The patient subsequently recovered fully from this episode of vancomycin-induced agranulocytosis, but he eventually died of other causes. Vancomycin-related leukopenia has been reported, but the severely depressed white blood cell count and myeloid hypoplasia observed in this patient have not previously been described. Vancomycin must be excluded as the cause of leukopenia in any patient who is receiving this drug.


Subject(s)
Agranulocytosis/chemically induced , Vancomycin/adverse effects , Adult , Anti-Glomerular Basement Membrane Disease/complications , Anti-Glomerular Basement Membrane Disease/therapy , Cellulitis/complications , Cellulitis/drug therapy , Combined Modality Therapy , Drug Therapy, Combination , Humans , Leukopenia/chemically induced , Male
9.
Am J Surg Pathol ; 20(3): 346-54, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8772789

ABSTRACT

Five cases of clinically aggressive, keratin-positive malignant lymphomas of B-cell type with unusual immunophenotypes were studied. All cases were extranodal: two from the stomach, one from soft tissue, one from the skin, and one from the spleen. These tumors were undifferentiated large-cell neoplasms that showed reactivity for low-molecular-weight keratin 8, but they were negative for keratin 19; three cases were also positive for epithelial membrane antigen. The immunohistochemical diagnosis was complicated by the fact that two of these cases lacked reactivity for leukocyte common antigen and three were CD20 negative. These findings simulated the immunophenotype of a carcinoma and led to an initial misdiagnosis of carcinoma. Although only two cases showed immunohistochemical evidence of B-cell lineage (CD20+), all five cases were documented as B-cell lymphomas on the basis of the clonal immunoglobulin heavychain gene rearrangement, as demonstrated by polymerase chain reaction (PCR) in all the cases and by Southern blot hybridization in three cases; all cases were negative for T-cell markers, and three cases showed germline configuration for T-cell receptor beta-chain. One case was strongly CD30 positive and represented large-cell anaplastic lymphoma of B-cell type. Our results show that some B-cell lymphomas can have unusual and confusing immunophenotypes, including keratin positivity and leukocyte antigen negativity. Use of PCR-based molecular genetic demonstration of clonal immunoglobulin heavychain gene rearrangement is helpful in establishing the correct diagnosis in such cases.


Subject(s)
Keratins/metabolism , Lymphoma, B-Cell/metabolism , Lymphoma, Large B-Cell, Diffuse/metabolism , Lymphoma, Non-Hodgkin/metabolism , Aged , Female , Gene Rearrangement , Humans , Immunoglobulin Heavy Chains/genetics , Immunohistochemistry , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Non-Hodgkin/genetics , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Molecular Biology , Phenotype , Polymerase Chain Reaction
10.
Am J Surg Pathol ; 16(2): 175-83, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1346359

ABSTRACT

The relatively frequent association of hematologic neoplasia and primary mediastinal germ cell tumors has been reported. Of these hematologic malignancies, nine were classified as malignant histiocytosis or acute monoblastic leukemia, and all occurred in males. We now report on a patient who was phenotypically female, with 46XY gonadal dysgenesis, and who developed a true histiocytic malignancy that presented as a large hepatic tumor and also involved the spleen, right kidney, and lymph nodes. Twenty-six months before the development of the histiocytic malignancy, an ovarian malignant teratoma with yolk sac elements was removed; the patient subsequently received chemotherapy. The neoplasm was composed of large pleomorphic cells and the histiocytic nature was established by cytologic, cytochemical, immunologic, and ultrastructural studies. In the course of her illness, the patient developed classic acute monoblastic leukemia 8 months after the diagnosis of histiocytic malignancy. Karyotypic analysis of the hepatic tumor, bone marrow, and blood showed 46XY gonadal dysgenesis. We believe that this is the first reported case of a phenotypically female patient who developed these two rare malignancies. It suggests that the association between germ cell tumors and histiocytic malignancy in genotypically male individuals may not be coincidental or secondary to therapy, but may be a phenomenon related to dysgenetic gonads in the presence of a Y chromosome.


Subject(s)
Gonadal Dysgenesis, 46,XY/complications , Histiocytic Sarcoma/complications , Ovarian Neoplasms/complications , Teratoma/complications , Adolescent , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Biomarkers, Tumor/analysis , CD11 Antigens , DNA, Neoplasm/genetics , Female , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics , Gonadal Dysgenesis, 46,XY/pathology , Histiocytic Sarcoma/pathology , Humans , Immunohistochemistry , Karyotyping , Liver/chemistry , Liver/pathology , Liver/ultrastructure , Lymphocytes/chemistry , Lymphocytes/pathology , Lymphocytes/ultrastructure , Muramidase/analysis , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Phenotype , S100 Proteins/analysis , Teratoma/genetics , Teratoma/pathology
11.
Hum Pathol ; 27(10): 1103-6, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8892600

ABSTRACT

We describe a case of simultaneous nodular sclerosing Hodgkin's disease and a granulocytic sarcoma in a cervical lymph node without any previous therapy. The condition evolved into acute myelogenous leukemia approximately 8 months after the initial diagnosis of the granulocytic sarcoma. The unexpected presence of a granulocytic sarcoma made the diagnosis challenging, and appropriate immunohistochemical studies were required for accurate diagnosis. To the best our knowledge, this is the first report of synchronous Hodgkin's disease and granulocytic sarcoma with eventual development of acute myelogenous leukemia.


Subject(s)
Hodgkin Disease/pathology , Leukemia, Myeloid/pathology , Neoplasms, Multiple Primary/pathology , Sarcoma/pathology , Aged , Hodgkin Disease/therapy , Humans , Immunohistochemistry , Leukemia, Myeloid/etiology , Leukemia, Myeloid, Acute/etiology , Leukemia, Myeloid, Acute/pathology , Male , Neoplasms, Multiple Primary/etiology , Sarcoma/therapy
12.
Hum Pathol ; 20(12 Suppl 1): 1-137, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2689323

ABSTRACT

The classification of non-Hodgkin's lymphomas (NHLs) has been traditionally based on analysis of histologic sections and has been supplemented more recently by immunologic marker studies. It was the purpose of the present study to illustrate, side-by-side, sections and Romanowsky-stained imprints from the same surgical specimen from practically all categories of immunophenotyped NHLs, including rare and atypical variants that were difficult to classify from the histologic sections alone. Our results indicate that imprint cytology may reveal nuclear and cytoplasmic details not discernible in even the best tissue sections and that it may be selectively helpful in contributing to the classification of NHLs. Our results also show that the relative value of imprint cytology in the classification of malignant lymphomas varies greatly among categories. Specifically, we have found that imprints assist in three ways: the recognition of plasmacytoid features in small cell lymphocytic lymphomas, the recognition of plasmacytoid immunoblastic lymphoma, and the differentiation between NHLs which may be difficult to distinguish histologically. These include (1) small lymphocytic lymphoma versus lymphocytic lymphoma of intermediate differentiation, (2) true histiocytic malignancies versus large cell malignant lymphomas with abundant cytoplasm and/or phagocytosis, (3) anaplastic myeloma versus plasmacytoid immunoblastic lymphoma, (4) large noncleaved versus plasmacytoid immunoblastic lymphoma, (5) lymphoblastic lymphoma versus diffuse small cleaved cell lymphoma, and (6) lymphoblastic lymphoma versus small noncleaved cell lymphoma. Lymph node imprints are easy to prepare and readily interpretable by those experienced in the study of abnormal blood and bone marrow films. Their value as an ancillary methodology aimed at optimal accuracy in the classification of NHLs should be recognized.


Subject(s)
Lymphoma, Non-Hodgkin/pathology , Humans , Immunohistochemistry/methods , Lymphoma, Non-Hodgkin/classification , Lymphoma, Non-Hodgkin/immunology , Terminology as Topic
13.
Hum Pathol ; 22(5): 422-30, 1991 May.
Article in English | MEDLINE | ID: mdl-1851718

ABSTRACT

A recent clinicopathologic study of a series of patients with monocytoid B-cell lymphoma (MBCL) indicated that there is a frequent association between MBCL and Sjögren's syndrome (SS) and raised the possibility of a relationship between these two disease entities. To further investigate the possible relationship of MBCL and SS, we studied pathologic and clinical characteristics of 13 patients with MBCL who had clinically documented SS. In all patients, the lymphoma had the characteristic morphologic features of MBCL, and immunologic and molecular hybridization studies confirmed the B-cell nature of the lymphoma. Twelve of the 13 patients were female, with a median age of 66 years at diagnosis. Eleven had localized disease and presented with either salivary gland or cervical lymph node enlargement; one patient presented with a breast mass, and another with generalized lymphadenopathy and hepatosplenomegaly. In five of 13 patients, the MBCL was associated with or progressed to large cell lymphoma. In two patients, there was bilateral involvement of the parotid gland; one had a synchronous high-grade lymphoma in both parotid glands. In two patients, bone marrow biopsies showed involvement by MBCL. Eleven patients are alive 2 to 55 months after the diagnosis of MBCL. One patient died with the disease 8 months after the initial diagnosis. Another patient died of an unrelated cause without evidence of disease 16 months after the diagnosis of MBCL. We conclude that there is a more than fortuitous association between MBCL and SS. This concept is consistent with previously reported observations of reactive monocytoid B cells in patients with benign lymphoepithelial lesions of salivary glands, which may result from selective homing of reactive monocytoid B lymphocytes to the benign lymphoepithelial lesions and their subsequent neoplastic transformation.


Subject(s)
Lymphoma, B-Cell/pathology , Monocytes/pathology , Sjogren's Syndrome/pathology , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/immunology , Autoimmune Diseases/complications , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , B-Lymphocytes/pathology , Blotting, Southern , Female , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/immunology , Humans , Immunophenotyping , Lymphoma, B-Cell/genetics , Male , Middle Aged , Sjogren's Syndrome/genetics
14.
Am J Clin Pathol ; 104(2): 199-203, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7639196

ABSTRACT

Conventional cytogenetic data and fluorescence in situ hybridization (FISH) interphase cytogenetic studies have shown that trisomy 12 is found in many cases of B-cell chronic lymphocytic leukemia (B-CLL). Several reports indicate that +12 is an acquired numerical cytogenetic abnormality, and may be associated with a worse prognosis or more extensive disease. Wright-Giemsa-stained blood or bone marrow smears obtained after initial diagnosis, and subsequent lymph node cells, bone marrow aspirate smears, or effusions were retrospectively studied from five patients whose disease underwent morphologic transformation from typical B-CLL to a high grade lymphoproliferative disease (Richter's syndrome). Using an alpha-satellite DNA probe to the centromere of chromosome 12, trisomy 12 was found in a proportion of cells from all five specimens with high grade lymphoproliferative disease, but in only one of five samples collected before transformation. These data suggest that +12 is an acquired cytogenetic abnormality in CLL and has a high frequency in Richter's syndrome. Because only a subpopulation of the neoplastic cells contain an extra copy of chromosome 12, it is unlikely that this numerical abnormality plays a direct role in transformation to high grade lymphoproliferative disease.


Subject(s)
Cell Transformation, Neoplastic/genetics , Chromosomes, Human, Pair 12/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphoma, B-Cell/genetics , Trisomy/genetics , Bone Marrow/pathology , Cell Transformation, Neoplastic/pathology , Humans , In Situ Hybridization, Fluorescence , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, B-Cell/pathology , Lymphoma, Non-Hodgkin/genetics , Lymphoma, Non-Hodgkin/pathology
15.
Am J Clin Pathol ; 93(6): 822-7, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2161182

ABSTRACT

Plasmacytoid T-cell lymphoma (PTL) is a rare lymphoma with unique morphologic, immunologic, and clinical features. Thus far, only three cases have been reported, each terminating in myeloid leukemia. The macrophage/monocyte rather than T-cell origin of "plasmacytoid T-cells" in reactive lymph nodes has been suggested in the past, but there has been no extensive investigation to demonstrate whether the PTLs are also of this lineage. The authors now report on a patient with PTL who had a long history of clinically stable idiopathic myelofibrosis. Immunocytochemical staining of the neoplastic plasmacytoid cells, with a large panel of monoclonal antibodies used on fresh-frozen and paraffin-embedded tissue sections, showed that the neoplastic cells expressed several macrophage/monocyte-associated markers, i.e., CD31, CD36 (thrombospondin receptor), and CD68 (KP1). Other markers of the macrophage/monocyte lineage (e.g., CD11b, CD11c, CD16) were absent. The neoplastic cells lacked B-cell-associated antigens and lacked most T-cell-associated markers, with the exception of CD2 and CD4. These findings are in close agreement with those of previous studies on normal plasmacytoid T-cells and support the macrophage/monocytic origin of PTL. Molecular hybridization studies provided additional support for the nonlymphoid origin of the plasmacytoid cells by demonstrating the absence of T-cell-receptor beta-chain and immunoglobulin heavy-chain gene rearrangements in the neoplastic cells. The results of the authors' studies indicate that "plasmacytoid T-cell lymphoma" associated with a chronic myeloproliferative disorder is of macrophage/monocyte lineage.


Subject(s)
Lymphoma/pathology , Primary Myelofibrosis/pathology , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , Humans , Immunoenzyme Techniques , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/ultrastructure , Lymph Nodes/pathology , Lymph Nodes/ultrastructure , Lymphoma/complications , Lymphoma/genetics , Lymphoma/immunology , Macrophages/immunology , Macrophages/ultrastructure , Microscopy, Electron , Middle Aged , Phenotype , Plasma Cells/immunology , Plasma Cells/ultrastructure , Primary Myelofibrosis/genetics , Primary Myelofibrosis/immunology , T-Lymphocytes/immunology
16.
Am J Clin Pathol ; 112(2): 248-55, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10439806

ABSTRACT

We report 5 cases of intravascular lymphoma (IVL) initially diagnosed by bone marrow aspiration and biopsy. Each patient had generalized symptoms; 1 also had neurologic deficits. CBC counts revealed anemia (4 patients), thrombocytopenia (4 patients), or mild leukopenia (1 patient). The bone marrow biopsy specimen was diagnostic in each case. Lymphoma cells were present in small groups or single file in sinusoids (in 1 patient, sinusoids were distended markedly by IVL) and were detected in bone marrow aspirate smears (4 patients) and peripheral blood smears (all patients). Immunohistochemical studies demonstrated that every neoplasm was of B-cell lineage, CD20+, positive for other B-cell antigens, and CD3- or CD43-. Immunophenotypic studies revealed at least 2, and possibly 3, distinct immunophenotypic groups of B-cell IVL: CD20+ CD5+ (3 neoplasms), CD20+ CD5- CD10+ (1 neoplasm), and CD20+ CD5- CD10 unknown (1 neoplasm). B-cell IVL may be detected by morphologic examination of peripheral blood and bone marrow, and involvement of these sites may be more common than is reported in the literature. Immunophenotypic studies are helpful in establishing the diagnosis and suggest that B-cell IVL is a heterogeneous group of neoplasms that may arise from more than 1 normal B-cell precursor.


Subject(s)
Bone Marrow/pathology , Lymphoma, B-Cell/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Vascular Neoplasms/diagnosis , Aged , Biomarkers, Tumor/analysis , Biopsy, Needle , Bone Marrow/chemistry , Female , Flow Cytometry , Hematologic Tests , Humans , Immunoenzyme Techniques , Lymphoma, B-Cell/chemistry , Lymphoma, B-Cell/mortality , Lymphoma, Large B-Cell, Diffuse/chemistry , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Survival Rate , Vascular Neoplasms/chemistry , Vascular Neoplasms/mortality
17.
Obstet Gynecol ; 95(6 Pt 2): 1022-4, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10808012

ABSTRACT

BACKGROUND: Hemophagocytic syndrome is characterized by nonmalignant histiocytes that undergo uncontrolled phagocytosis of normal hematopoietic cells. Clinical severity ranges from complete recovery to rapid deterioration and death. CASE: Thrombocytopenia was discovered upon routine initial prenatal evaluation of a 24-year-old, gravida 2, para 1, at 29 weeks' gestation with a history of necrotizing lymphadenitis. Cytopenia and elevated transaminases developed, followed by hyperpyrexia. The patient delivered and her postpartum course was complicated by coagulopathy, multiorgan failure, and death. Bone marrow biopsy confirmed hemophagocytic syndrome. CONCLUSION: Early diagnosis of hemophagocytic syndrome during pregnancy might be helped by recognizing symptoms and signs, including a history of necrotizing lymphadenitis, and obtaining a bone marrow biopsy.


Subject(s)
Histiocytosis, Non-Langerhans-Cell/diagnosis , Pregnancy Complications , Adult , Epstein-Barr Virus Infections/complications , Fatal Outcome , Female , Histiocytic Necrotizing Lymphadenitis/complications , Histiocytosis, Non-Langerhans-Cell/virology , Humans , Pregnancy
18.
Life Sci ; 61(24): PL 373-81, 1997.
Article in English | MEDLINE | ID: mdl-9399638

ABSTRACT

The antioxidant efficacy of aspalatone (APT; acetyl salicylic acid maltol ester), a new antiplatelet agent, has been characterized in vivo as well as in vitro, and several observations indicated that the antioxidant could prevent the neuroexcitation caused by oxidative stress. In this report, the effect of APT was evaluated on kainic acid (KA)-induced neurotoxicity, since the neurotoxicity induced by KA is, at least in part, mediated via the formation of free radicals. The results showed that pretreatments with APT or maltol (MAL) significantly attenuated seizure activity, oxidative stress (lipid peroxidation and protein oxidation) and the loss of hippocampal neurons induced by KA. On the other hand, the pretreatments with aspirin (ASP), ASP together with MAL or vitamin E failed to protect against the toxicity produced by KA suggesting that the mechanism of action for APT on the KA-induced neurotoxicity is different from that of ASP. These finding raise the possibility that salicylmaltol, a metabolite of APT, plays a role in preventing the neurotoxicity evoked by KA. Therefore, our results suggest that an APT-related antioxidant mechanism, which is linked to the MAL moiety, is involved in the neuroprotective effect against KA.


Subject(s)
Aspirin/analogs & derivatives , Kainic Acid/toxicity , Neuroprotective Agents/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Animals , Aspirin/pharmacology , Brain/drug effects , Brain/pathology , Lipid Peroxidation/drug effects , Male , Oxidative Stress , Rats , Rats, Sprague-Dawley
19.
Arch Pathol Lab Med ; 114(12): 1264-7, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2252423

ABSTRACT

There is a significantly increased incidence of malignant lymphoma in patients with acquired immunodeficiency syndrome (AIDS). The lymphomas are usually of a high grade and of B-cell phenotype. While the frequent presence of reactive monocytoid B lymphocytes in patients with AIDS-related lymphadenopathy has recently been documented in several studies, to our knowledge, there are no reported cases of monocytoid B-cell lymphoma, the neoplastic counterpart of monocytoid B lymphocytes, in patients with AIDS. We now describe a human immunodeficiency virus (HIV)-positive patient with HIV-related lymphadenopathy in whom monocytoid B-cell lymphoma developed during the course of his disease. The morphologic and immunologic features of the lymphoma were characteristic of monocytoid B-cell lymphoma, and the involved lymph node exhibited a reversed CD4/CD8 ratio. Moreover, using the polymerase chain reaction, we were able to demonstrate HIV genome in DNA extracted from the lymph node tissue. To our knowledge, this is the first report of a case of monocytoid B-cell lymphoma occurring in an HIV-positive patient and in which we were able, by using a sensitive molecular biologic technique, to demonstrate HIV sequence in paraffin-embedded, fixed lymph node sections.


Subject(s)
Acquired Immunodeficiency Syndrome/genetics , HIV/genetics , Lymphoma, B-Cell/genetics , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/pathology , Adult , Antigens, Neoplasm/analysis , Base Sequence , DNA, Neoplasm/analysis , Humans , Lymph Nodes/pathology , Lymphoma, B-Cell/etiology , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/pathology , Male , Molecular Sequence Data , Polymerase Chain Reaction
20.
Hong Kong Med J ; 8(2): 114-22, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11937666

ABSTRACT

Sedation during diagnostic or therapeutic procedures must be safe and comfortable for patients. To achieve this, additional suitably qualified staff must be available throughout the procedure to administer sedation and monitor the patient. Anaesthesiologists possess the necessary knowledge and skills to perform sedation safely but are often unavailable. Non-anaesthesiologists performing sedation should be fully trained in the physiology of sedation, the pharmacology of sedatives and analgesics, the monitoring of patients, and in airway support, ventilatory care, and cardiopulmonary resuscitation. The presence of an anaesthesiologist is desirable when dealing with patients at high-risk of complications. Good sedation practice involves presedation assessment and optimal selection of patients, careful monitoring and support from dedicated staff, and adherence to recovery and discharge criteria.


Subject(s)
Conscious Sedation , Hypnotics and Sedatives/administration & dosage , Adult , Analgesia, Patient-Controlled , Child , Clinical Competence , Conscious Sedation/adverse effects , Conscious Sedation/methods , Conscious Sedation/standards , Environment , Guidelines as Topic , Humans , Hypnotics and Sedatives/adverse effects , Monitoring, Physiologic , Quality of Health Care , Safety Management
SELECTION OF CITATIONS
SEARCH DETAIL